Chemistry:3-Keto-5α-abiraterone
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | 17-(3-Pyridyl)-5α-androst-16-en-3-one |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H31NO |
| Molar mass | 349.518 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Keto-5α-abiraterone, also known as 17-(3-pyridyl)-5α-androst-16-en-3-one, is an active metabolite of abiraterone acetate that has been found to possess androgenic activity and to stimulate prostate cancer progression.[1][2] It is formed as follows: abiraterone acetate to abiraterone by esterases; abiraterone to Δ4-abiraterone by 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase; and Δ4-abiraterone to 3-keto-5α-abiraterone by 5α-reductase.[1][2] 3-Keto-5α-abiraterone may counteract the clinical effectiveness of abiraterone acetate, and so inhibition of its formation using the 5α-reductase inhibitor dutasteride is being investigated as an adjunct to abiraterone acetate in the treatment of prostate cancer.[1][2]
References
- ↑ 1.0 1.1 1.2 "Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy". Nature 533 (7604): 547–51. May 2016. doi:10.1038/nature17954. PMID 27225130. PMC 5111629. Bibcode: 2016Natur.533..547L. https://dash.harvard.edu/bitstream/handle/1/29626087/5111629.pdf?sequence=1.
- ↑ 2.0 2.1 2.2 "Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation". Translational Cancer Research 3 (5): S529–S531. 2016. doi:10.21037/tcr.2016.07.35. PMID 30815377.
 |  |
